- Home
- OKYO vs ACET Comparison
OKYO vs ACET Comparison
Compare OKYO & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OKYO | ACET |
|---|---|---|
| Founded | 2007 | 1947 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.7M | 71.3M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | OKYO | ACET |
|---|---|---|
| Price | $2.17 | $8.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.00 | ★ $65.33 |
| AVG Volume (30 Days) | ★ 252.8K | 206.2K |
| Earning Date | 07-18-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $7.15 |
| 52 Week High | $3.35 | $17.44 |
Technical Indicators
Market Signals| Indicator | OKYO | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 79.56 |
| Support Level | $1.97 | $7.76 |
| Resistance Level | $3.20 | $8.55 |
| Average True Range (ATR) | 0.30 | 0.45 |
| MACD | -0.04 | -0.13 |
| Stochastic Oscillator | 17.80 | 93.85 |
Price Performance
Historical ComparisonAbout OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.